3,683 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Abel Hall LLC

Abel Hall LLC purchased a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,683 shares of the company’s stock, valued at approximately $248,000.

A number of other hedge funds also recently bought and sold shares of AZN. Charles Schwab Investment Management Inc. lifted its position in shares of AstraZeneca by 237.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 123,018 shares of the company’s stock valued at $8,331,000 after acquiring an additional 86,610 shares in the last quarter. Deutsche Bank AG lifted its position in shares of AstraZeneca by 0.5% in the third quarter. Deutsche Bank AG now owns 496,986 shares of the company’s stock valued at $33,656,000 after acquiring an additional 2,426 shares in the last quarter. Fiera Capital Corp lifted its position in shares of AstraZeneca by 31.0% in the third quarter. Fiera Capital Corp now owns 5,295 shares of the company’s stock valued at $359,000 after acquiring an additional 1,254 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of AstraZeneca by 6.8% in the third quarter. William Blair Investment Management LLC now owns 75,344 shares of the company’s stock valued at $5,102,000 after acquiring an additional 4,776 shares in the last quarter. Finally, E Fund Management Co. Ltd. lifted its position in shares of AstraZeneca by 24.3% in the third quarter. E Fund Management Co. Ltd. now owns 5,496 shares of the company’s stock valued at $372,000 after acquiring an additional 1,076 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on AstraZeneca in a research report on Thursday, May 30th. They issued a “buy” rating and a $97.00 target price on the stock. Argus lifted their price objective on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, BMO Capital Markets lifted their price objective on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $88.00.

AstraZeneca Stock Up 0.1 %

NASDAQ:AZN traded up $0.06 during midday trading on Friday, reaching $79.59. The company had a trading volume of 2,055,322 shares, compared to its average volume of 3,761,780. The firm has a market capitalization of $246.77 billion, a price-to-earnings ratio of 39.01, a PEG ratio of 1.43 and a beta of 0.48. The stock’s fifty day simple moving average is $75.46 and its 200-day simple moving average is $69.36. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $80.86. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.